New Treatment for TED
Dr Michael Yen discusses Lumvoa’s recent FDA approval for active and chronic thyroid eye disease
Clinical Scorecard: New Treatment for TED
At a Glance
| Category | Detail |
|---|
| Condition | Thyroid Eye Disease (TED) |
| Key Mechanisms | IGF-1R antagonist targeting |
| Target Population | Patients with active and chronic thyroid eye disease |
| Care Setting | Oculoplastic Surgery and Ophthalmology |
Key Highlights
- FDA approved Lumvoa™ (veligrotug-vvze) for TED treatment.
- Demonstrated significant proptosis reduction and diplopia resolution.
- 70% of patients experienced over 2mm proptosis reduction.
- Low rates of adverse events reported in clinical trials.
- Treatment administered over 12 weeks with five intravenous infusions.
Guideline-Based Recommendations
Diagnosis
- Conduct a thorough clinical exam for accurate diagnosis.
Management
- Discuss treatment expectations and compliance with patients.
Monitoring & Follow-up
- Periodic follow-up examinations are essential during treatment.
Risks
- Potential for reactivation or relapse of symptoms.
Patient & Prescribing Data
Patients diagnosed with active or chronic thyroid eye disease.
Treatment effects may be observed as early as three weeks.
Clinical Best Practices
- Ensure accurate diagnosis to avoid mismanagement.
- Emphasize the importance of patient compliance for successful outcomes.
- Monitor for potential relapses and adjust treatment as necessary.
Related Resources & Content
